Post-earnings recap
Reported
Wed, Nov 6, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a loss per share of $0.48, but did not provide revenue figures or guidance. The stock fell by 1.6% following the announcement, reflecting investor uncertainty due to the lack of detailed financial information and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.48 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to ongoing clinical development. However, they did not provide specific updates or guidance for future performance.
Management did not provide specific revenue figures or guidance for future quarters.
The focus remains on advancing clinical programs.